Hyperthyroidism: Causes, Symptoms, and Treatment Options

Hyperthyroidism (also called thyrotoxicosis when caused by any source of excess hormone) is a state of excess circulating thyroxine (T4) and triiodothyronine (T3). It is not a single disease. The most common underlying cause is Graves' disease, an autoimmune disorder; other causes include toxic multinodular goiter, a single toxic adenoma, thyroiditis, excess iodine exposure, and certain drugs such as amiodarone. Treatment options include the antithyroid medications methimazole (brand name Tapazole) and propylthiouracil (PTU), radioactive iodine (iodine-131) ablation, and thyroidectomy. This article does not cover dosing for an individual patient; dosing and treatment selection require an evaluation by the treating clinician.

The direct answer

A suppressed TSH (below roughly 0.4 mIU/L on most assay reference ranges) with an elevated free T4 or free T3 defines overt hyperthyroidism. When TSH is low but free T4 and free T3 are still within the normal range, the condition is called subclinical hyperthyroidism. Graves' disease accounts for the large majority of hyperthyroidism cases in countries with adequate dietary iodine, and the standard first-line treatment for most non-pregnant adults with Graves' disease is methimazole, with radioactive iodine and surgery reserved as alternatives chosen based on goiter size, eye disease, pregnancy plans, and patient preference. This is the established framework in current American Thyroid Association (ATA) guidance; exact percentages cited below for remission rates, cardiovascular risk, and treatment success vary across studies and should be confirmed against the current guideline text rather than treated as fixed numbers.

What is actually established, and what is not

Established: Hyperthyroidism is diagnosed by a suppressed TSH plus elevated free T4 or free T3. Graves' disease is the leading cause in iodine-sufficient regions. Methimazole, radioactive iodine, and thyroidectomy are all recognized treatment options with different speed, side-effect, and reversibility profiles. Methimazole crosses the placenta and carries a documented risk of rare birth defects (including aplasia cutis and choanal atresia) with first-trimester exposure, which is why PTU is preferred in the first trimester and iodine-131 is contraindicated throughout pregnancy.

Plausible but not settled from the sources available here: Precise remission rates after antithyroid drug courses, the exact magnitude of atrial fibrillation or fracture risk from subclinical hyperthyroidism, and the degree of benefit from selenium supplementation in autoimmune thyroid disease. These numbers appear repeatedly in secondary literature, but a specific figure (for example, "40 to 50% remission" or "threefold atrial fibrillation risk") should be checked against the current ATA guideline or a systematic review before it is used as a clinical decision point.

Not established here: Any individualized dose, monitoring interval, or treatment choice for a specific patient. That decision belongs to the treating clinician and depends on age, cardiac status, pregnancy plans, goiter size, and eye disease.

Graves' disease: mechanism and diagnosis

Graves' disease is an autoimmune condition in which antibodies called thyroid-stimulating immunoglobulins (TSI) bind to and continuously activate the TSH receptor, driving thyroid hormone production independent of normal pituitary feedback. The classic clinical triad is diffuse goiter, thyroid eye disease (proptosis, lid retraction, and periorbital changes), and, less commonly, pretibial myxedema. Thyroid eye disease results from a related but distinct autoimmune process affecting orbital tissue and can progress somewhat independently of thyroid hormone control; when severe, it may require corticosteroid therapy or orbital and eyelid surgery. A 2026 case series on eyelid retraction correction in thyroid eye disease describes surgical spacer techniques used when retraction does not resolve with medical management, illustrating that eye disease is managed on a separate track from the endocrine disorder (surgical outcomes for eyelid retraction in thyroid eye disease).

Diagnosis of Graves' disease is supported by a suppressed TSH with elevated free T4 or free T3, plus either a positive TSH-receptor antibody (TRAb/TSI) test or diffusely elevated uptake on a radioactive iodine uptake scan. There is also emerging interest in psychological and physiological stress as a factor in the onset and course of Graves' disease; a systematic review addressing this question is in the literature, though the strength and direction of that association is still being characterized and should not be treated as a mechanism a patient can act on today (stress and the course of Graves' disease, systematic review).

Antithyroid drug, radioactive iodine, or surgery: a decision framework

There is no universally "best" treatment for Graves' disease or another cause of hyperthyroidism. The choice depends on a small number of factors that change the calculus meaningfully. This is not a substitute for a clinician's recommendation, but it lays out the tradeoffs a reader should expect to discuss.

Two exceptions cut across all of the above: active moderate-to-severe thyroid eye disease and pregnancy each override the default recommendation. If either applies, the standard treatment ladder does not simply apply as written, and the discussion with an endocrinologist should start from that fact rather than from goiter size or symptom severity alone.

Subclinical hyperthyroidism: when watching is reasonable

Subclinical hyperthyroidism is a low but detectable TSH with free T4 and free T3 still in the normal range. Many patients have no symptoms. Observational studies have linked more pronounced TSH suppression (below about 0.1 mIU/L) to higher rates of atrial fibrillation and reduced bone density, particularly in postmenopausal women, but the exact magnitude of this risk varies by study population and should be treated as an association rather than a precise number to plan around. Guideline-based practice generally favors treatment when TSH is persistently below 0.1 mIU/L, and treatment is more strongly considered in patients 65 or older or those with cardiac risk factors even at milder TSH suppression (roughly 0.1 to 0.4 mIU/L). Younger, asymptomatic patients with milder suppression are often followed with repeat TSH testing rather than treated immediately.

Hyperthyroidism in pregnancy

Uncontrolled hyperthyroidism during pregnancy is associated with higher rates of preterm birth, low birth weight, preeclampsia, and, rarely, thyroid storm. Graves' disease is the most common cause of hyperthyroidism requiring treatment during pregnancy. PTU is preferred in the first trimester because of methimazole's association with rare fetal malformations; many clinicians switch back to methimazole after the first trimester to reduce the risk of PTU-associated liver injury, which is rare but serious. Radioactive iodine is contraindicated throughout pregnancy and lactation. A 2026 review of hyperthyroidism management in pregnancy discusses these trimester-specific strategies and the tradeoffs between the two drugs in more detail (management of hyperthyroidism in pregnancy, 2026); a treating obstetric and endocrine team should individualize the plan, since trimester-specific TSH targets and monitoring intervals are not one-size-fits-all.

Related conditions readers often confuse with hyperthyroidism

Hashimoto's thyroiditis is an autoimmune condition that usually causes hypothyroidism (underactive thyroid) rather than hyperthyroidism, and it is the most common cause of hypothyroidism in iodine-sufficient countries. In its early phase, however, damaged thyroid follicles can release stored hormone and transiently raise T4 and T3, a pattern sometimes called Hashitoxicosis that can be mistaken for Graves' disease on lab tests alone. Elevated anti-thyroid peroxidase (anti-TPO) antibodies support the Hashimoto's diagnosis. Selenium supplementation has been studied as a way to lower anti-TPO titers, but whether that antibody reduction changes clinically meaningful outcomes such as progression to overt hypothyroidism is not settled, and routine supplementation is not a standard guideline recommendation.

Hypothyroidism, the opposite state, is treated with levothyroxine (synthetic T4), generally titrated to a TSH target that most guidelines place around 0.5 to 2.5 mIU/L for younger adults, with a somewhat higher acceptable target in older adults. TSH is typically rechecked 6 to 8 weeks after a dose change because it takes that long for the pituitary-thyroid axis to re-equilibrate.

Thyroid nodules are common on ultrasound, and most are benign. A nodule that autonomously secretes hormone (a toxic adenoma or toxic multinodular goiter) is a separate mechanism for hyperthyroidism distinct from Graves' disease. Ultrasound features such as microcalcifications, irregular margins, or a taller-than-wide shape raise suspicion for malignancy and typically prompt fine-needle aspiration biopsy at a smaller size threshold than a nodule without those features.

When symptoms need urgent, not routine, evaluation

Thyroid storm is a rare but life-threatening hypermetabolic crisis that can occur in undertreated or untreated severe hyperthyroidism, often triggered by infection, surgery, or abrupt medication discontinuation. Fever, marked tachycardia, altered mental status, and severe agitation in someone with known or suspected hyperthyroidism warrant emergency evaluation rather than a routine outpatient visit. Reported mortality estimates for thyroid storm vary across case series and eras of treatment; the exact figure should be treated as an estimate rather than a fixed statistic, but the underlying point, that this is a medical emergency, is not in question.

Symptoms side by side

Both untreated hyperthyroidism and untreated hypothyroidism carry cardiovascular consequences over time (atrial fibrillation risk with hyperthyroidism, elevated LDL cholesterol with hypothyroidism), which is one reason neither condition should be left undiagnosed once symptoms and lab findings point toward it.